177472-30-9

Basic information

• Product Name: Levofloxacin Related Compound C (25 mg) ((S)-ethyl 9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylate)
• Synonyms: Ethyl 8-Fluoro-3-Methyl-9-(4-Methyl-piperazin-1-yl)-6-oxo-2,3-dihydro- 6H-1-oxa-3a-aza-phenalene-5-carboxylate;Levofloxacin USP RC C;Levofloxacin Related CoMpound C;Levofloxacin Ethyl Ester;ethyl 9-fluoro-3-Methyl-10-(4-Methylpiperazin-1-yl)-7-oxo-3,7-dihydro-2H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylate;ethyl (S)-9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylate;Levofloxacin Related Compound C (25 mg) ((S)-ethyl 9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylate);Levofloxacin Impurity 10
• CAS NO: 177472-30-9
• Molecular Formula: C18H20FN3O4
• Molecular Weight: 361.3675032
• Mol File: 177472-30-9.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 559.6°C at 760 mmHg
• Flash Point: 292.3°C
• Appearance: /
• Density: 1.36g/cm³
• Vapor Pressure: 1.48E-12mmHg at 25°C
• Refractive Index: 1.623
• Storage Temp.: 2-8°C
• Solubility: DMSO (Slightly), Methanol (Slightly)
• PKA: 7.37±0.42(Predicted)
• CAS DataBase Reference: Levofloxacin Related Compound C (25 mg) ((S)-ethyl 9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylate)(CAS DataBase Reference)
• NIST Chemistry Reference: Levofloxacin Related Compound C (25 mg) ((S)-ethyl 9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylate)(177472-30-9)
• EPA Substance Registry System: Levofloxacin Related Compound C (25 mg) ((S)-ethyl 9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylate)(177472-30-9)

Safety Data

• Hazardous Substances Data: 177472-30-9(Hazardous Substances Data)

Usage

Uses

Levofloxacin Ethyl Ester (Levofloxacin USP Related Compound C) is an impurity of Levofloxacin (L360000).

InChI:InChI=1/C20H24FN3O4/c1-4-27-20(26)14-10-24-12(2)11-28-19-16(24)13(18(14)25)9-15(21)17(19)23-7-5-22(3)6-8-23/h9-10,12H,4-8,11H2,1-3H3/t12-/m0/s1

Upstream product

• 64-17-5 ethanol 
• 82419-36-1 ofloxacin 
• 113933-55-4 ethyl 2-<2,3,5-trifluoro-4-(4-methyl-1-piperazinyl)-benzoyl>-3-dimethylaminoacrylate 
• 138998-47-7 ethyl α<(N,N-dimethylamino)methylene>-2,3,4,5-tetrafluoro-β-oxobenzenepropanoate 
• 94695-48-4 2,3,4,5-tetrafluorobenzoyl chloride 
• 924-99-2 ethyl 3-(dimethylamino)acrylate 
• 177472-28-5 (S)-ethyl 3-(1-hydroxypropan-2-ylamino)-2-(2,3,5-trifluoro-4-(4-methylpiperazin-1-yl)benzoyl)acrylate 

Downstream Products

• 100986-85-4 levofloxacin 

Relevant articles and documents

Preparation method of levofloxacin and intermediates thereof

The invention relates to a preparation method of levofloxacin and intermediates thereof, and belongs to the field of medicinal chemistry. The preparation method comprises the following steps of: carrying out amino substitution and ring closing reaction on a fluorine-substituted substrate to integrate a plurality of intermediates into a one-pot reaction, and hydrolyzing under acidic conditions to obtain levofloxacin. According to the method, the reaction operation is simplified, the production period is greatly shortened, multiple times of after-treatment are not needed, emission of three wastes is reduced, the method is more environmentally friendly, the reaction yield is increased by about 20% compared with the prior art, and the method is suitable for industrial amplification.

Design, synthesis, and docking studies of novel ofloxacin analogues as antimicrobial agents

A number of novel ofloxacin analogues were synthesized by modifying the carboxylic acid at C-6. To investigate the antimicrobial data on structural basis, in-silico docking studies of the tested compounds into the crystal structure of topoisomerase II using Autodock vina 4.0 program was performed in order to predict the affinity and orientation of the synthesized compounds at the activities. R2 values show good agreement with predicted binding affinities obtained by molecular docking studies. Also, it is verified by in-vitro antimicrobial screening, where all the compounds were most active against Staphylococcus aureus, Staphylococcus epidermidis and Bacillus subtilis. Among these compounds 3a, 3b, 3f showed good MIC (0.125 μg/ml). Springer Science+Business Media, LLC 2011.

Spectroscopic studies on the interaction between Pr(III) complex of an ofloxacin derivative and bovine serum albumin or DNA

The binding properties on [PrL2(NO3)](NO 3)2 (L = 9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1- piperaziny)-7-oxo-7Hpyrido[1,2,3-de]-1,4-benzoxazine-6-carbaldehyde benzoyl hydrazone) to bovine serum albumin (BSA